+

WO2008008805A3 - Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells - Google Patents

Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells Download PDF

Info

Publication number
WO2008008805A3
WO2008008805A3 PCT/US2007/073202 US2007073202W WO2008008805A3 WO 2008008805 A3 WO2008008805 A3 WO 2008008805A3 US 2007073202 W US2007073202 W US 2007073202W WO 2008008805 A3 WO2008008805 A3 WO 2008008805A3
Authority
WO
WIPO (PCT)
Prior art keywords
target cells
toxins
clostridial
targeting activity
altered targeting
Prior art date
Application number
PCT/US2007/073202
Other languages
French (fr)
Other versions
WO2008008805A2 (en
Inventor
Lance E Steward
Joseph Francis
Ester Fernandez-Salas
Marcella A Gilmore
Shengwen Li
Kei Roger Aoki
Original Assignee
Allergan Inc
Lance E Steward
Joseph Francis
Ester Fernandez-Salas
Marcella A Gilmore
Shengwen Li
Kei Roger Aoki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, Lance E Steward, Joseph Francis, Ester Fernandez-Salas, Marcella A Gilmore, Shengwen Li, Kei Roger Aoki filed Critical Allergan Inc
Priority to CA002657521A priority Critical patent/CA2657521A1/en
Priority to AU2007272517A priority patent/AU2007272517B2/en
Priority to EP07812774A priority patent/EP2038299A2/en
Priority to JP2009519645A priority patent/JP2009543558A/en
Publication of WO2008008805A2 publication Critical patent/WO2008008805A2/en
Publication of WO2008008805A3 publication Critical patent/WO2008008805A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an altered target domain; polynucleotide molecules encoding such modified Clostridial toxins; and methods of producing such modified Clostridial toxins.
PCT/US2007/073202 2006-07-11 2007-07-11 Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells WO2008008805A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002657521A CA2657521A1 (en) 2006-07-11 2007-07-11 Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
AU2007272517A AU2007272517B2 (en) 2006-07-11 2007-07-11 Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
EP07812774A EP2038299A2 (en) 2006-07-11 2007-07-11 Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
JP2009519645A JP2009543558A (en) 2006-07-11 2007-07-11 Modified clostridial toxin with enhanced translocation ability and enhanced targeting activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80705906P 2006-07-11 2006-07-11
US60/807,059 2006-07-11

Publications (2)

Publication Number Publication Date
WO2008008805A2 WO2008008805A2 (en) 2008-01-17
WO2008008805A3 true WO2008008805A3 (en) 2008-04-10

Family

ID=38924120

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/073202 WO2008008805A2 (en) 2006-07-11 2007-07-11 Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells

Country Status (5)

Country Link
EP (1) EP2038299A2 (en)
JP (1) JP2009543558A (en)
AU (1) AU2007272517B2 (en)
CA (1) CA2657521A1 (en)
WO (1) WO2008008805A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
CA2658260A1 (en) * 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
AU2009259034B2 (en) 2008-06-12 2013-10-31 Ipsen Bioinnovation Limited Suppression of cancers
JP5728380B2 (en) 2008-06-12 2015-06-03 シンタクシン リミテッドＳｙｎｔａｘｉｎ Ｌｉｍｉｔｅｄ Suppression of neuroendocrine disease
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
CN102422158B (en) 2009-03-13 2015-04-08 阿勒根公司 Immuno-based retargeted endopeptidase activity assays
US20100303783A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
US20100303756A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Interleukin Retargeted Endopepidases
US20100303798A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Neurotrophin Retargeted Endopepidases
US20100303789A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Neurotrophin Retargeted Endopepidases
US20100303791A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases
US20100303794A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
US20100303757A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
US8198229B2 (en) * 2009-05-29 2012-06-12 Allergan, Inc. Methods of treating urogenital-neurological disorders using galanin retargeted endopepidases
US20100303788A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
CN102822196B (en) 2010-01-25 2014-12-17 阿勒根公司 Methods of intracellular conversion of single-chain proteins into their di-chain form
WO2011146704A1 (en) 2010-05-20 2011-11-24 Allergan, Inc. Degradable clostridial toxins
AU2011315962B2 (en) 2010-10-14 2016-06-02 Allergan, Inc. Targeted delivery of Targeted Exocytosis Modulators to the sphenopalatine ganglion for treatment of headache disorders
US20120244188A1 (en) 2011-03-25 2012-09-27 Allergan, Inc. Treatment of Sensory Disturbance Disorders
US20120251575A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Involuntary Movement Disorders
US20120251574A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US20120251573A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Neuroendocrine Disorders
US20120251518A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
US20120258132A1 (en) 2011-03-29 2012-10-11 Allergan, Inc. Vagal Nerve-Based Disorders
US20120251519A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Smooth Muscle Disorders
US20120251515A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Cosmesis Disorders
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
WO2012174123A1 (en) 2011-06-13 2012-12-20 Allergan, Inc. Treatment of psychological trauma
US20130171122A1 (en) 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders
US20140056870A1 (en) * 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
JP2015534814A (en) * 2012-10-31 2015-12-07 イプセン バイオイノベーション リミテッド Recombinant Clostridium botulinum neurotoxin
GB201219602D0 (en) 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
EP2934571B1 (en) 2012-12-18 2018-05-30 Allergan, Inc. Prophylactic treatment of herpes recurrence
EP3822286A1 (en) * 2015-01-09 2021-05-19 Ipsen Bioinnovation Limited Cationic neurotoxins
EA201890587A1 (en) 2015-08-27 2018-09-28 Президент Энд Феллоуз Оф Гарвард Колледж COMPOSITIONS AND METHODS FOR TREATING PAIN
TWI822723B (en) 2018-01-29 2023-11-21 英商艾普森生物製藥有限公司 NON-NEURONAL SNARE-CLEAVING BOTULINUM NEUROTOXINS, IN VITRO METHOD OF CLEAVING hSNAP-23, AND USE OF MODIFIED BoNT/A L-CHAIN PROTEASE
WO2019224184A1 (en) 2018-05-21 2019-11-28 Ipsen Biopharm Limited Suppression of bone cancer-induced allodynia
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
US20220016221A1 (en) 2018-12-05 2022-01-20 Ipsen Biopharm Limited Treatment of symptoms of traumatic brain injury
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
EP4313120A1 (en) 2021-03-30 2024-02-07 Ipsen Biopharm Limited Treatment of pain & inflammatory disorders
US20250066755A1 (en) 2021-03-30 2025-02-27 Ipsen Biopharm Limited Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
AU2023351434A1 (en) 2022-09-30 2025-03-06 Ipsen Biopharm Limited Clostridial neurotoxin for use in a treatment of bladder pain syndrome
GB202404021D0 (en) 2024-03-20 2024-05-01 Ipsen Biopharm Ltd Cell-based neurotoxin assay

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359347A2 (en) * 1988-08-15 1990-03-21 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
WO1998007864A1 (en) * 1996-08-23 1998-02-26 Microbiological Research Authority Camr (Centre For Applied Microbiology & Research) Recombinant toxin fragments
WO2001014570A1 (en) * 1999-08-25 2001-03-01 Allergan Sales, Inc. Activatable recombinant neurotoxins
WO2004024909A2 (en) * 2002-09-12 2004-03-25 Health Protection Agency Recombinant colstridium neurotoxin fragments
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
WO2006099590A2 (en) * 2005-03-15 2006-09-21 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1982997B1 (en) * 2004-09-01 2012-08-08 Allergan, Inc. Degradable clostridial toxins
DE102004043009A1 (en) * 2004-09-06 2006-03-23 Toxogen Gmbh Transport protein for introducing chemical compounds into nerve cells
CA2658260A1 (en) * 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359347A2 (en) * 1988-08-15 1990-03-21 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
WO1998007864A1 (en) * 1996-08-23 1998-02-26 Microbiological Research Authority Camr (Centre For Applied Microbiology & Research) Recombinant toxin fragments
WO2001014570A1 (en) * 1999-08-25 2001-03-01 Allergan Sales, Inc. Activatable recombinant neurotoxins
WO2004024909A2 (en) * 2002-09-12 2004-03-25 Health Protection Agency Recombinant colstridium neurotoxin fragments
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
WO2006099590A2 (en) * 2005-03-15 2006-09-21 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2038299A2 *

Also Published As

Publication number Publication date
JP2009543558A (en) 2009-12-10
AU2007272517A1 (en) 2008-01-17
AU2007272517B2 (en) 2013-09-26
EP2038299A2 (en) 2009-03-25
CA2657521A1 (en) 2008-01-17
WO2008008805A2 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
WO2008008805A3 (en) Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
WO2008008803A3 (en) Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
WO2008105901A3 (en) Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
WO2006099590A3 (en) Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
ATE518882T1 (en) CLOSTRIDIAL TOXINS ACTIVATED WITH CLOSTRIDIENTOXIN
ATE416191T1 (en) DEGRADABLE CLOSTRIDIAL TOXINS
WO2006125000A3 (en) Method for the production of resveratrol in a recombinant oleaginous microorganism
MX369263B (en) Degradable clostridial toxins.
JP2009508489A5 (en)
WO2006124999A3 (en) Method for the production of resveratrol in a recombinant bacterial host cell
WO2008053232A3 (en) Mycotoxin-reducing composition
WO2006043178A3 (en) Enzymes
WO2009132220A3 (en) Isoprene synthase variants for improved microbial production of isoprene
WO2008073446A3 (en) Methods and systems related to transmission of nutraceutical associated information
WO2008033830A3 (en) Complexity-aware encoding
WO2010014632A3 (en) Methods and compositions for improving the production of products in microorganisms
MX2010003194A (en) Glucoamylase variants with altered properties.
WO2008054821A3 (en) Mutant hydrolase proteins with enhanced kinetics and functional expression
WO2006102652A3 (en) Expression of soluble, active eukaryotic glycosyltransferases in prokaryotic organisms
IL177467A0 (en) Media for clostridium bacterium and processes for obtaining a clostridial toxin
WO2010014631A3 (en) Methods and compositions for improving the production of products in microorganisms
WO2008061256A3 (en) Tracking usage of portable media device
WO2010138387A3 (en) Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
WO2006047404A3 (en) Methods for the production of food grade extracts
BR112012022603A2 (en) highly productive isopropyl alcohol producing bacteria

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07812774

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2657521

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2007812774

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007272517

Country of ref document: AU

Ref document number: 2007812774

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009519645

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2007272517

Country of ref document: AU

Date of ref document: 20070711

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0715456

Country of ref document: BR

Free format text: APRESENTE FOLHAS DO RELATORIO DESCRITIVO E DO DESENHO ADAPTADOS AO AN NO127/1997.

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0715456

Country of ref document: BR

Free format text: PEDIDO RETIRADO POR NAO CUMPRIMENTO DA EXIGENCIA FORMULADA NA RPI 2200 DE 05/03/2013

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载